PATENT CLAIM ANALYSIS

Application Number: 15758582
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-08
Patent Classification: ["514", "252180"]

Abstract:
According to the present invention, there is provided a pharmaceutical composition for treating Philadelphia chromosome positive lymphocytic leukemia, including a thalidomide derivative and BCR-ABL tyrosine kinase inhibitor. According to the present invention there is also provided a method of treating Philadelphia chromosome positive lymphocytic leukemia, including administering a thalidomide derivative and a BCR-ABL tyrosine kinase inhibitor to a patient suffering from Philadelphia chromosome positive lymphocytic leukemia.

Claim (Index 4):
The pharmaceutical composition according to  claim 2 , wherein the IKZF1 gene mutation lacks at least four exons.

Metadata:
- Claim Count in Document: 15.0
- Percentile: 90.0
- Lexical Diversity: 2.02857
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['13922141', '11909559', '12026554', '12901139', '13122137']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7134612150463734
- 35 USC 102 Novelty (BERT): 0.5357256743877955
- Combined Prediction Score: 0.6956876609805156
- Mean Citation Score: 272.617282
- Max Citation Score: 282.5456
- Similarity Product: 136.12453919463158

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test